SAN FRANCISCO--(BUSINESS WIRE)--Encellin, a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing ...
Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel ...
LAS VEGAS, Dec. 16, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes ...
Researchers have built a synthetic-cell platform that can be chemically adjusted in real time, sidestepping a long-standing ...
CiQUS researchers introduces an innovative chemical strategy to create biomimetic structures with greater efficiency. The design of more versatile and controllable synthetic cells could unlock new ...